SCHEMBL7674372

SCHEMBL7674372

CC(C)(NS(=O)(=O)c1ccc(NC(=O)c2ccccc2)cc1)C(=O)O

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.63
PRMT1 Q99873 2/20 0.61
KMT2A Q03164 4/20 0.61
MEN1 O00255 3/20 0.61
CA12 O43570 1/20 0.58
CA1 P00915 1/20 0.58
CA2 P00918 1/20 0.58
CA9 Q16790 1/20 0.58
HPGD P15428 1/20 0.58
MMP9 P14780 2/20 0.57
MMP2 P08253 1/20 0.57
ALDH1A1 P00352 1/20 0.56
SMN1; SMN2 Q16637 4/20 0.54
MAPT P10636 3/20 0.54
HTT P42858 1/20 0.54
MAPK1 P28482 2/20 0.53
KDM4E B2RXH2 1/20 0.53
NPC1 O15118 1/20 0.53
RAB9A P51151 1/20 0.53
PTPN1 P18031 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19198126 0.89 LMNA (0.66) LMNAPRMT1KMT2AMEN1CA12
SCHEMBL7670734 0.86 LMNA (0.56) LMNAPRMT1KMT2AMEN1CA12
SCHEMBL10402270 0.82 BCAT1 (0.50) LMNAKMT2AMEN1CA1CA2
SCHEMBL3074331 0.81 LMNA (0.56) LMNAPRMT1KMT2AMEN1CA12
SCHEMBL14675960 0.79 ADAMTS4 (0.54) KMT2AMEN1CA12CA1CA2
SCHEMBL27450474 0.78 HSD17B10 (0.71) LMNAPRMT1KMT2AMEN1CA12
SCHEMBL12010897 0.78 KMT2A (0.91) LMNAPRMT1KMT2AMEN1CA12
SCHEMBL3107195 0.77 PRMT1 (0.75) LMNAPRMT1KMT2AMEN1CA12
SCHEMBL14676772 0.77 ALDH1A1 (0.58) KMT2AMEN1CA1CA2ALDH1A1
SCHEMBL7671460 0.77 NAMPT (0.59) KMT2AMEN1ALDH1A1SMN1; SMN2NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6403644-B1 FOR PREVENTION AND/OR TREATMENT OF DISEASES INDUCED BY OVEREXPRESSION AND EXCESS ACTIVITY OF MATRIX METALLOPROTEINASE; FOR EXAMPLE, RHEUMATOID, ARTHROSTEITIS, UNUSUAL BONE RESORPTION, OSTEOPOROSIS, PERIODONTITIS ONO PHARMACEUTICAL CO., LTD. (JP) 2002-06-11 US claimed
EP-0757037-A2 Sulfonylamino acid derivatives as metalloproteinase inhibitors ONO PHARMACEUTICAL CO., LTD. (JP) 1997-02-05 EP claimed
US-6403644-B1 FOR PREVENTION AND/OR TREATMENT OF DISEASES INDUCED BY OVEREXPRESSION AND EXCESS ACTIVITY OF MATRIX METALLOPROTEINASE; FOR EXAMPLE, RHEUMATOID, ARTHROSTEITIS, UNUSUAL BONE RESORPTION, OSTEOPOROSIS, PERIODONTITIS ONO PHARMACEUTICAL CO., LTD. (JP) 2002-06-11 US disclosed
US-6177466-B1 Sulfonylamino acid derivatives ONO PHARMACEUTICAL CO., LTD. (JP) 2001-01-23 US disclosed
EP-0757037-A2 Sulfonylamino acid derivatives as metalloproteinase inhibitors ONO PHARMACEUTICAL CO., LTD. (JP) 1997-02-05 EP disclosed